Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02713256 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

A Phase 2 study of Graves Disease, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target
3
Study locations

NCT02713256 is a Phase 2 study of Graves Disease that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 15 participants, below the 308-participant average among 11 other Graves Disease trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02713256, a Phase 2 study of Graves Disease, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target
3
Study locations

Study Summary

An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease

Conditions Studied

Graves Disease

Interventions

  • DRUG CFZ533

Study Locations (3)

Hawaii

  • Novartis Investigative Site - Honolulu

Minnesota

  • Novartis Investigative Site - Rochester

Other

  • Novartis Investigative Site - Mainz

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2016-04-19
Est. Completion 2017-04-24
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02713256

The ClinicalTrials.gov registry entry for NCT02713256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 11 other Graves Disease trials with a reported enrollment target (95% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Graves Disease appearing as the primary indexed condition, and to 1 intervention - of which CFZ533 is the first listed.

NCT02713256 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Hawaii, Minnesota, Other.

Frequently Asked Questions

What is clinical trial NCT02713256 about?

NCT02713256 is a clinical study titled "A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease". An open label study to evaluate the safety and efficacy of CFZ533 following 12 weeks treatment in patients with Graves' disease

What is the current status of trial NCT02713256?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2016-04-19. Estimated completion is 2017-04-24.

What conditions does trial NCT02713256 study?

This clinical trial studies the following conditions: Graves Disease.

What interventions are being tested in trial NCT02713256?

The interventions under investigation include: CFZ533 (DRUG).

Who is sponsoring clinical trial NCT02713256?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02713256 being conducted?

This trial has 3 study locations across Hawaii, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graves Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Graves Disease

All registered trials for this condition

Hawaii

All trials with a study site in Hawaii

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.